News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/emapalumab-gamifant-230.jpg)
FDA approves first treatment for primary HLH
- Author:
- Jen Smith
The U.S.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/prescriptions_Credit_CDC_230.jpg)
Triplet produces ‘unprecedented’ ORR in PI-refractory MM
- Author:
- Jen Smith
Phase 2 results suggest a three-drug regimen may improve response rates in patients with proteasome inhibitor (PI)-refractory multiple myeloma (MM...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/haut-team-220.jpg)
Education can improve adherence to VTE prophylaxis
- Author:
- Jen Smith
Education can improve adherence to venous thromboembolism (VTE) prophylaxis among hospitalized patients, according to researchers. They assessed...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/thrombus_credit_Andre_E.X._Brown_230.jpg)
Score can predict thrombosis in ITP
- Author:
- Jen Smith
New research suggests a scoring system can predict the risk of thrombosis in patients with immune thrombocytopenia (ITP) who are taking...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/navaldaver-220.jpg)
‘Encouraging’ phase 2 results in rel/ref AML
- Author:
- Jen Smith
The combination of azacitidine and nivolumab produced “encouraging” results in a phase 2 trial of patients with relapsed or refractory acute...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/elotuzumab-400-small-230.jpg)
FDA approves elotuzumab combo for rel/ref MM
- Author:
- Jen Smith
The U.S.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/NickolaiPodoltsevMDPhD-230.jpg)
Underused PV treatments save lives, doc says
- Author:
- Jen Smith
Researchers have found evidence to suggest that phlebotomy and hydroxyurea (HU) provide real-world benefits for older patients with polycythemia...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/vials_drug_Bill_Branson_230.jpg)
Denosumab fights osteoporosis in TDT patients
- Author:
- Jen Smith
Denosumab can be effective against osteoporosis caused by transfusion-dependent thalassemia (TDT), according to research published in Blood...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/young_adult_pt_receiving_chemo_Credit_Rhoda_Baer_220.jpg)
Novel risk factors for febrile neutropenia in NHL, other cancers
- Author:
- Jen Smith
A retrospective study has revealed new potential risk factors for chemotherapy-induced febrile neutropenia (FN) in patients with solid tumors and...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/bazarbachi-ali-js-230.jpg)
Understanding the role of HSCT in PTCL
- Author:
- Jen Smith
DUBROVNIK, CROATIA—Hematopoietic stem cell transplant (HSCT) can be hit-or-miss in patients with peripheral T-cell lymphomas (PTCLs), according to...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/scientist_using_a_computer_Credit_Darren_Baker_230.jpg)
FDA issues draft guidance on MRD
- Author:
- Jen Smith
The U.S.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/valkovic-js.jpg)
Questions surround MRD assessment in MM
- Author:
- Jen Smith
DUBROVNIK, CROATIA—Clinical trials are needed to answer the many questions related to minimal residual disease (MRD) assessment in multiple...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/CMML-simon-caulton-230.jpg)
The challenges of diagnosing CMML
- Author:
- Jen Smith
DUBROVNIK, CROATIA—Diagnosing chronic myelomonocytic leukemia (CMML) remains a challenge in 2018, according to a presentation at Leukemia and...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/kantarjian-hagop-js-240-v2.jpg)
Optimizing use of TKIs in CML
- Author:
- Jen Smith
DUBROVNIK, CROATIA—Long-term efficacy and toxicity should inform decisions about tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/majewska-eliza-230-js.jpg)
CDK8 inhibitor can fight AML, though it’s unclear how
- Author:
- Jen Smith
DUBROVNIK, CROATIA—The CDK8 inhibitor SEL120 has demonstrated preclinical activity against acute myeloid leukemia (AML), but the agent’s mechanism...